Henrike Westekemper

Henrike Westekemper

Auto-generated profile, based on publicly available information

Henrike Westekemper

Department of Ophthalmology, University Hospital Essen, 45147 Essen, Germany

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 March 2022 in European Journal of Cancer
Verified
Journal Article
Closed access
GLGeorg Lodde
Georg Lodde
PJPhilipp Jansen
Philipp Jansen
IMInga Möller
Inga Möller
ASAntje Sucker
Antje Sucker
Jessica HasselJessica Hassel
Jessica Hassel
KGKlaus G. Griewank
Klaus G. Griewank

30 August 2010 in British Journal of Ophthalmology
Verified
Journal Article
Open access
PDF file
HWHenrike Westekemper
Henrike Westekemper
SKSara Karimi
Sara Karimi
DSDaniela Süsskind
Daniela Süsskind
GAGerasimos Anastassiou
Gerasimos Anastassiou
MFMichael Freistühler
Michael Freistühler
FGFlorian Grabellus
Florian Grabellus
Background To analyse the expression of melanoma chondroitin sulfate proteoglycan (MCSP) and the preferentially expressed antigen of melanoma (PRAME) in conjunctival melanoma (CoM), lymph node (LN) metastases of cutaneous melanoma (CM) and conjunctival nevi (CoN) by immunohistology. Methods Immunohistology was performed in 70 samples of CoM, 25 of LN metastases of CM and 12 of CoN, and assessed by an immunoreactive score (0–12 points). Statistical analysis was performed to disclose relevant differences in the expression pattern. The diagnostic value of the markers was tested by receiver operating characteristics (ROC) analysis. Results MCSP and PRAME were expressed at significantly higher levels in CoM and LN metastases of CM than in CoN (p<0.0001). Within CoM, an MCSP expression 9.0 points. ROC analysis showed an area under the curve of 91.3% for MCSP (p=0.0002) and 93.8% for PRAME (p<0.0001). Conclusions MCSP and PRAME are differentially expressed in conjunctival melanomas and nevi. MCSP might have an impact on the risk for recurrence in being inversely correlated to the event. Both markers have high potential to discriminate CoM from CoN. The results indicate that immunohistological characteristics gain relevance in the assessment of CoM.

17 December 2013 in BMC Ophthalmology
Verified
Journal Article
Open access
PDF file
MSMaurice Schallenberg
Maurice Schallenberg
HWHenrike Westekemper
Henrike Westekemper
KSKlaus-Peter Steuhl
Klaus-Peter Steuhl
DMDaniel Meller
Daniel Meller
Mooren’s ulcer is a severe ulcerative inflammation of the cornea. The exact pathogenesis remains unclear. Therefore many therapies of Mooren’s ulcer are recommended in literature. To shed more light on the ongoing question of optimal treatment of severe progressive Mooren’s ulcer, we here report on a retrospective case series of patients treated with systemic immunosuppressive therapy and additional amniotic membrane transplantation.

11 July 2012 in Graefe's Archive for Clinical and Experimental Ophthalmology
Verified
Journal Article
Closed access
PDF file
HWHenrike Westekemper
Henrike Westekemper
MFMichael Freistuehler
Michael Freistuehler
NBNorbert Bornfeld
Norbert Bornfeld
KSKlaus-Peter Steuhl
Klaus-Peter Steuhl
MSMax Scheulen
Max Scheulen
RHRalf A. Hilger
Ralf A. Hilger

13 April 2021 in Cancers
Verified
Journal Article
Open access
PDF file
EBEva Biewald
Eva Biewald
TKTobias Kiefer
Tobias Kiefer
DGDirk Geismar
Dirk Geismar
SSSabrina Schlüter
Sabrina Schlüter
AMAnke Manthey
Anke Manthey
NBNorbert Bornfeld
Norbert Bornfeld
Despite the increased risk of subsequent primary tumors (SPTs) external beam radiation (EBRT) may be the only therapeutic option to preserve a retinoblastoma eye. Due to their physical properties, proton beam therapy (PBT) offers the possibility to use the effectiveness of EBRT in tumor treatment and to decisively reduce the treatment-related morbidity. We report our experiences of PBT as rescue therapy in a retrospectively studied cohort of 15 advanced retinoblastoma eyes as final option for eye-preserving therapy. The average age at the initiation of PBT was 35 (14–97) months, mean follow-up was 22 (2–46) months. Prior to PBT, all eyes were treated with systemic chemotherapy and a mean number of 7.1 additional treatments. Indication for PBT was non-feasibility of intra-arterial chemotherapy (IAC) in 10 eyes, tumor recurrence after IAC in another 3 eyes and diffuse infiltrating retinoblastoma in 2 eyes. Six eyes (40%) were enucleated after a mean time interval of 4.8 (1–8) months. Cataract formation was the most common complication affecting 44.4% of the preserved eyes, yet 77.8% achieved a visual acuity of >20/200. Two of the 15 children treated developed metastatic disease during follow-up, resulting in a 13.3% metastasis rate. PBT is a useful treatment modality as a rescue therapy in retinoblastoma eyes with an eye-preserving rate of 60%. As patients are at lifetime risk of SPTs consistent monitoring is mandatory.

23 January 2012 in British Journal of Ophthalmology
Verified
Journal Article
Closed access
PDF file
HWHenrike Westekemper
Henrike Westekemper
MFMichael Freistuehler
Michael Freistuehler
GAGerasimos Anastassiou
Gerasimos Anastassiou
GNGordon Nareyeck
Gordon Nareyeck
NBNorbert Bornfeld
Norbert Bornfeld
RHRalf A Hilger
Ralf A Hilger
Objective Two conjunctival cell lines (CRMM-1 and CRMM-2) have been established from recurrent conjunctival melanoma. The authors examined the chemosensitivity of these cell lines to cytotoxic substances and combinations to identify substances that inhibit cell growth efficiently in vitro. Material and methods CRMM-1 and CRMM-2 were exposed to cisplatin, mitomycin C (MMC), all-trans-retinoic-acid (ATRA), fotemustine or imatinib for 24 h. Sulforhodamine-B assays were used to assess the IC50. Isobolograms were performed to test possible synergism and antagonism with ATRA or imatinib. Results Cisplatin and MMC were efficient to inhibit the growth of CRMM-1 and CRMM-2. Combination of imatinib with MMC showed additive antitumoral effect on both cell lines. Combined treatment of imatinib with fotemustine or cisplatin resulted in antagonism. Strong antagonisms were also obtained with ATRA and fotemustine or cisplatin in both cell lines. A synergism was found for ATRA and mitomycin or imatinib in CRMM-2, in contrast to CRMM-1, where antagonism was obtained. Conclusions Cisplatin and MMC inhibit cell growth in conjunctival melanoma cell lines. The potential of ATRA was evident only in combination with MMC or imatinib in CRMM-2 cells. Imatinib and mitomycin increased their efficiency under combination therapy.